These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8616024)

  • 1. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
    Wisløff F; Eika S; Hippe E; Hjorth M; Holmberg E; Kaasa S; Palva I; Westin J
    Br J Haematol; 1996 Mar; 92(3):604-13. PubMed ID: 8616024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
    Wisløff F; Hjorth M
    Br J Haematol; 1997 Apr; 97(1):29-37. PubMed ID: 9136939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
    Wisløff F; Hjorth M; Kaasa S; Westin J
    Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.
    Wisløff F; Gulbrandsen N
    Acta Oncol; 2000; 39(7):809-13. PubMed ID: 11145438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
    Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
    Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
    Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
    Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
    Knop S; Mateos MV; Dimopoulos MA; Suzuki K; Jakubowiak A; Doyen C; Lucio P; Nagy Z; Usenko G; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Losava G; Fujisaki T; Garg M; Wang J; Wroblewski S; Kudva A; Gries KS; Fastenau J; San-Miguel J; Cavo M
    BMC Cancer; 2021 Jun; 21(1):659. PubMed ID: 34078314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
    Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
    J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20.
    Ahmadzadeh A; Yekaninejad MS; Saffari M; Pakpour AH; Aaronson NK
    Asian Pac J Cancer Prev; 2016; 17(1):255-9. PubMed ID: 26838220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU
    Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-Related Quality of Life and Satisfaction With Health Care: Relation to Clinical Stage in Mexican Patients With Multiple Myeloma.
    Balderas-Peña LM; Miranda-Ruvalcaba C; Robles-Espinoza AI; Sat-Muñoz D; Ruiz MG; García-Luna E; Nava-Zavala AH; Rubio-Jurado B
    Cancer Control; 2019; 26(1):1073274819831281. PubMed ID: 30786721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
    Gulbrandsen N; Wisløff F; Nord E; Lenhoff S; Hjorth M; Westin J;
    Eur J Haematol; 2001 May; 66(5):328-36. PubMed ID: 11422413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
    Gulbrandsen N; Wisløff F; Brinch L; Carlson K; Dahl IM; Gimsing P; Hippe E; Hjorth M; Knudsen LM; Lamvik J; Lenhoff S; Løfvenberg E; Nesthus I; Nielsen JL; Turesson I; Westin J;
    Med Oncol; 2001; 18(1):65-77. PubMed ID: 11778972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.
    Seefat MR; Stege CAM; Lissenberg-Witte BI; Levin MD; Timmers GJ; Hoogendoorn M; Ypma PF; Klein SK; Velders GA; Westerman M; Strobbe L; Durdu-Rayman N; Davidis-van Schoonhoven MA; van Kampen RJW; Dijk AC; Koster A; Silbermann MH; van der Spek E; Beeker A; Erjavec Z; de Graauw NCHP; Leys MBL; Sonneveld P; van de Donk NWCJ; Nasserinejad K; Blommestein HM; Cucchi DGJ; Zweegman S
    Eur J Cancer; 2024 Aug; 207():114153. PubMed ID: 38870747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.
    Cocks K; Cohen D; Wisløff F; Sezer O; Lee S; Hippe E; Gimsing P; Turesson I; Hajek R; Smith A; Graham L; Phillips A; Stead M; Velikova G; Brown J;
    Eur J Cancer; 2007 Jul; 43(11):1670-8. PubMed ID: 17574838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
    Westin J
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in multiple myeloma: clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument.
    Espinoza-Zamora JR; Portilla-Espinosa CM; Labardini-Méndez JR; Cervera E; Niesvisky R; Oñate-Ocaña LF
    Ann Hematol; 2015 Jun; 94(6):1017-24. PubMed ID: 25563595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.